Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Int.biotech. (IBT) Share Price

Price 918.00p on 30-01-2026 at 19:40:07
Change -12.00p -1.29%
Buy 920.00p
Sell 912.00p
Last Trade: Sell 834.00 at 918.00p
Day's Volume: 83,252
Last Close: 918.00p
Open: 930.00p
ISIN: GB0004559349
Day's Range 914.00p - 930.00p
52wk Range: 480.00p - 1,000.00p
Market Capitalisation: £292.87m
VWAP: 924.46043p
Shares in Issue: 31.90m

Int.biotech. (IBT) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 834 918.00p Uncrossing Trade
16:35:04 - 30-Jan-26
Sell* 500 912.8082p Ordinary
16:29:46 - 30-Jan-26
Sell* 1,143 912.781p Negotiated Trade
16:28:47 - 30-Jan-26
Sell* 28 912.00p SI Trade
16:28:25 - 30-Jan-26
Sell* 256 914.00p Automatic Execution
16:28:25 - 30-Jan-26
Sell* 347 913.20p Ordinary
16:01:59 - 30-Jan-26
Buy* 1,000 921.36p Suspected BUY Trade
15:59:56 - 30-Jan-26
Buy* 216 919.188p Ordinary
15:56:20 - 30-Jan-26
Buy* 2 924.00p SI Trade
15:56:20 - 30-Jan-26
Buy* 216 919.20p Ordinary
15:51:00 - 30-Jan-26
See more Int.biotech. trades

Int.biotech. (IBT) Share Price History

Time period:
to
Date Open High Low Close Volume
30th Jan 2026 (Fri) 930.00 930.00 914.00 918.00 83,252
29th Jan 2026 (Thu) 940.00 942.00 926.00 930.00 97,993
28th Jan 2026 (Wed) 952.00 956.00 940.00 940.00 70,909
27th Jan 2026 (Tue) 954.00 962.00 950.00 954.00 61,176
26th Jan 2026 (Mon) 974.00 974.00 950.00 958.00 106,789
23rd Jan 2026 (Fri) 992.00 994.00 980.00 980.00 83,485
22nd Jan 2026 (Thu) 980.00 990.00 972.00 982.00 56,370
21st Jan 2026 (Wed) 964.00 970.00 962.00 970.00 40,180
20th Jan 2026 (Tue) 950.00 964.00 942.00 964.00 82,263
19th Jan 2026 (Mon) 960.00 964.00 952.00 960.00 103,581
16th Jan 2026 (Fri) 966.00 974.00 964.00 970.00 64,502
15th Jan 2026 (Thu) 970.00 986.00 966.00 972.00 67,590
14th Jan 2026 (Wed) 962.00 968.00 956.00 968.00 76,946
13th Jan 2026 (Tue) 964.00 966.00 954.00 954.00 69,060
12th Jan 2026 (Mon) 970.00 976.00 956.00 968.00 85,003
9th Jan 2026 (Fri) 976.00 986.00 968.00 986.00 137,977
8th Jan 2026 (Thu) 974.00 980.00 968.00 968.00 90,166
7th Jan 2026 (Wed) 948.00 972.00 944.00 970.00 111,724
6th Jan 2026 (Tue) 938.00 948.00 930.00 946.00 55,447
5th Jan 2026 (Mon) 984.00 984.00 934.00 934.00 123,356
2nd Jan 2026 (Fri) 980.00 982.00 960.00 966.00 65,561
1st Jan 2026 (Thu) 964.00 964.00 964.00 964.00 0
See more Int.biotech. price history

Int.biotech. (IBT) Regulatory News

Date Source Headline
30th Jan 2026 11:56 am RNS Net Asset Value(s)
29th Jan 2026 5:26 pm RNS-R QuotedData's In The HotSeat Special
29th Jan 2026 11:36 am RNS Net Asset Value(s)
28th Jan 2026 2:06 pm RNS Director/PDMR Shareholding
28th Jan 2026 2:06 pm RNS Director/PDMR Shareholding
28th Jan 2026 11:37 am RNS Net Asset Value(s)
27th Jan 2026 11:50 am RNS Net Asset Value(s)
26th Jan 2026 11:22 am RNS Net Asset Value(s)
23rd Jan 2026 11:45 am RNS Net Asset Value(s)
22nd Jan 2026 11:37 am RNS Net Asset Value(s)
See more Int.biotech. regulatory news

Int.biotech. (IBT) Share News

UK dividends calendar - next 7 days

16th Jan 2026 15:52

Read More

UK dividends calendar - next 7 days

22nd Dec 2025 14:43

Read More

International Biotechnology beats benchmark with 0.7% NAV gain

6th Nov 2025 19:17

(Alliance News) - International Biotechnology Trust PLC on Thursday said its portfolio continued to outperform the sector benchmark as the company reported full-year results. Read More

IN BRIEF: International Biotechnology Trust notes Novo to buy Akero

9th Oct 2025 15:40

International Biotechnology Trust PLC - investor in biotech and life science companies - Notes portfolio firm Akero Therapeutics Inc as agreed to be taken over by Novo Nordisk AS in a deal worth up to EUR5.2 billion. Novo Nordisk will pay an initial USD54 per share, with a contingent portion of the deal worth USD6 per share. The Bagsvaerd, Denmark-based pharmaceuticals company will pay an initial EUR4.7 billion to buy the firm, and a potential additional payment of EUR500 million, hinging on US regulatory approval for key Akero treatment Efruxifermin. The deal adds Akero's Efruxifermin to Novo Nordisk's portfolio. The asset is aimed at treating metabolic dysfunction-associated steatohepatitis, a disease caused by fat buildup in the liver. Read More

International Biotechnology to raise unquoted exposure with Schroders

2nd Oct 2025 13:31

(Alliance News) - International Biotechnology Trust PLC on Thursday said it has partnered with Schroders Capital to access more investees in the earlier stages of development. Read More

See more Int.biotech. news
FTSE 100 Latest
Value10,223.54
Change51.78

Login to your account

Forgot Password?

Not Registered